Funded by the Bill and Melinda Gates Foundation, the TACT-CV study (2017-2020) is a multi-centre, open-label randomised trial to assess the efficacy, safety and tolerability of the Triple ACT artemether-lumefantrine+amodiaquine (AL+AQ) compared to the ACT artemether-lumefantrine (AL) in uncomplicated falciparum malaria in Cambodia and Vietnam that will run to 2020.
Malaria is endemic in many rural areas of Stung Treng, a province of over 110,000 people in the northeast of Cambodia bisected by the Mekong River and bordering Laos. In 2017, in partnership with the Cambodian National Centre for Parasitology, Entomology, and Malaria Control (CNM) MORU established a research station at Siem Pang health centre. The site features a study ward, offices, accommodation, and laboratory facilities – and is the Cambodia site for TACT-CV.© MORU 2019, Nicky Almasy.
Epidemiological studies in nearby villages map malaria and look at transmission patterns and understand forest-acquired malaria in collaboration with Professor Richard Maude, head of MORU Epidemiology.
In addition, public engagement activities providing health education in rural communities are coordinated by Nou Sanann and Pich Kunthea in collaboration with Professor Phaik Yeong Cheah, Head of MORU Bioethics. These activities can be followed on Facebook.